Trials / Terminated
TerminatedNCT07085468
A Study of LY3549492 in Healthy Weight Adult Participants
A Parallel-Group, Double-Blind Study to Investigate the Safety and Tolerability of LY3549492 Compared With Placebo in Adult Participants Aged 55 to 80 Years With a BMI of 22 to 25 kg/m2
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 55 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in adult participants with a healthy body max index (BMI) of 22 to 25 kilograms per square meter (kg/m2). Participation in the study will last about 13 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3549492 | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2025-07-21
- Primary completion
- 2025-08-14
- Completion
- 2025-08-14
- First posted
- 2025-07-25
- Last updated
- 2025-08-29
Locations
21 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07085468. Inclusion in this directory is not an endorsement.